secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2024-12-05T23:59:59+00:00
Accession:  0001104659-24-125774
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics receives FDA guidance for Phase 3 study of VCN-01 in metastatic pancreatic cancer
--------------------------------------------------------------------------------

- FDA advised stand-alone Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel; VIRAGE Phase 2b should not be expanded into Phase 3.
- FDA generally agreed with Theriva's proposed Phase 3 design; no additional chemotherapy needed for PDAC.
- VIRAGE Phase 2b enrollment completed; final patient follow-up is underway.
- Additional FDA meeting planned after VIRAGE completion to discuss Phase 3 protocol details.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465924125774/0001104659-24-125774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465924125774/tm2430229d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-125774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer